Boston Scientific
BSX
$44.03
-1.32%
Boston Scientific Corp. is a global medical device company specializing in less invasive technologies for interventional cardiology, cardiac rhythm management, endoscopy, neuromodulation, and urology. As a diversified leader in the medical devices industry, it competes with Medtronic, Abbott, and Johnson & Johnson, with a strong portfolio of innovative products and a global footprint where foreign sales account for roughly 36% of total revenue. The current investor narrative centers on the company's strategic $1.5 billion investment in MiRus to enter the high-growth TAVR market, which has garnered positive analyst attention, while the stock has experienced a severe drawdown of over 60% from its 52-week high, raising debates about whether the sell-off is overdone and presents a value opportunity.…
BSX
Boston Scientific
$44.03
Related headlines
Investment Opinion: Should I buy BSX Today?
Rating: Buy. Thesis: Boston Scientific is a fundamentally strong medical device company with accelerating revenue growth, expanding margins, and a compelling forward valuation that is not fully reflecting its earnings power. The consensus analyst rating is Strong Buy with an average target of $72.5, implying 64.7% upside.
Supporting Evidence: Revenue grew 11.6% YoY in Q1 2026 to $5.203 billion, with net margin expanding to 25.7% from 14.5% a year ago. The forward P/E of 11.9x is a deep discount to the trailing P/E of 48.6x, and the PEG ratio of 0.88 suggests undervaluation relative to growth. Free cash flow of $3.442 billion provides ample liquidity. The analyst low target of $55 still offers 24.9% upside, indicating limited downside risk.
Risks & Conditions: The primary risk is that forward earnings estimates prove too optimistic; if EPS growth disappoints, the stock could re-rate lower. A break below the 52-week low of $42.2 would invalidate the bullish thesis and could lead to further declines. This Buy rating would be downgraded to Hold if the stock fails to hold above $42 or if revenue growth decelerates below 8%. Overall, the stock appears undervalued relative to its growth and forward earnings, offering a favorable risk/reward for patient investors.
Sign up to view all
BSX 12-Month Price Forecast
The AI assessment is bullish with medium confidence. Boston Scientific's fundamental strength — double-digit revenue growth, expanding margins, and robust free cash flow — supports a positive outlook. The forward P/E of 11.9x is deeply discounted relative to the sector, and the PEG ratio of 0.88 suggests the stock is undervalued. However, the severe technical downtrend and the gap between trailing and forward earnings create uncertainty. The base case of a recovery to $72.5 is the most probable, but the stock's momentum must improve for this to materialize. An upgrade to high confidence would require a break above $50 resistance and sustained earnings beats.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $72.43 and implied upside of +64.5% versus the current price.
Average Target
$72.43
0 analysts
Implied Upside
+64.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$55 - $106
Analyst target range
Boston Scientific is covered by 28 analysts, with a consensus recommendation of 'Strong Buy' (mean rating 1.5 on a 1-5 scale). The average target price is $72.5, implying 64.7% upside from the current price of $44.03. The distribution is heavily bullish, with no sell ratings evident from the recent ratings data, which includes multiple 'Buy' and 'Outperform' ratings from firms like Mizuho, RBC Capital, Needham, and Jefferies. The target range spans from a low of $55.0 to a high of $106.0, representing 24.9% to 140.8% upside from current levels. The high target of $106 assumes a return to the stock's 52-week high territory, likely driven by successful TAVR market entry and margin expansion. The low target of $55 still implies significant upside, suggesting analysts believe the downside is limited. The wide spread between low and high ($51) indicates high uncertainty, but the fact that even the low target is above the current price reflects strong conviction in a recovery. Recent ratings have been uniformly positive, with no downgrades in the past month, reinforcing the bullish consensus. The strong analyst support provides a favorable backdrop, though the stock's severe decline suggests the market is pricing in more risk than analysts currently anticipate.
Drowning in data?
Find the real signal!
Bulls vs Bears: BSX Investment Factors
Boston Scientific presents a classic value trap vs. turnaround debate. On the bull side, the company has strong fundamentals: 11.6% revenue growth, expanding margins, a healthy balance sheet, and a forward P/E of 11.9x that suggests deep value. Analyst consensus is Strong Buy with 64.7% upside. On the bear side, the stock is in a severe downtrend, down 57.9% in the past year, with negative momentum and a high trailing P/E of 48.6x. The key tension is whether the forward earnings estimates are achievable: if the company delivers on its growth and margin targets, the stock is deeply undervalued; if it disappoints, the stock could fall further. Currently, the bull case has stronger evidence given the fundamental strength and analyst support, but the technical weakness warrants caution.
Bullish
- Strong Revenue Growth Trajectory: Revenue grew 11.6% YoY in Q1 2026 to $5.203 billion, with accelerating growth from 7.8% in Q2 2024. This consistent double-digit expansion underscores strong product cycles and market share gains.
- Significant Upside to Analyst Targets: The average analyst target of $72.5 implies 64.7% upside from the current $44.03, with even the low target of $55 offering 24.9% upside. The consensus is Strong Buy (1.5/5), reflecting high conviction in a recovery.
- Improving Profitability and Margins: Net margin expanded to 25.7% in Q1 2026 from 14.5% a year ago, and gross margin improved to 69.4% from 63.3%. Operating margin rose to 20.6%, indicating strong operating leverage.
- Attractive PEG Ratio: With a PEG ratio of 0.88 (below 1.0), the stock appears undervalued relative to its earnings growth rate. The forward P/E of 11.9x is near historical lows, suggesting the market is pricing in a recovery.
Bearish
- Severe Price Decline and Momentum: The stock has fallen 57.9% over the past year, vastly underperforming the S&P 500's +18.4%. The 3-month decline of 31.4% shows accelerating selling pressure, with no reversal signal yet.
- High Trailing P/E vs. Peers: The trailing P/E of 48.6x is elevated compared to the medical devices sector average of 20-30x. This premium may compress if growth disappoints or if the market re-rates the stock.
- Uncertainty Around TAVR Investment: The $1.5 billion MiRus investment is a bet on a new market. If clinical or commercial results underwhelm, as hinted by the March 30 trial results, the stock could face further downside.
- Low Relative Strength: Relative strength over 1 year is -76.3%, indicating persistent underperformance. The stock is trading near its 52-week low of $42.2, and a break below could trigger additional selling.
BSX Technical Analysis
Boston Scientific is in a sustained downtrend, with the stock price declining 57.9% over the past year, significantly underperforming the S&P 500's gain of 18.4%. The current price of $44.03 is trading at just 40.2% of its 52-week range (low $42.2, high $109.5), near the bottom of the range. This positioning near the 52-week low suggests the stock is deeply oversold and may represent a value opportunity, but it also reflects persistent selling pressure and a lack of bullish momentum. Short-term momentum remains negative, with a 1-month price change of -2.0% and a 3-month change of -31.4%, indicating that the downtrend is accelerating rather than stabilizing. The 1-month decline contrasts with the S&P 500's 0.3% gain over the same period, showing significant relative weakness. The RSI is not provided, but the continued price decline suggests oversold conditions may be present, though no reversal signal has emerged. The 52-week low of $42.2 serves as critical support; a break below this level could trigger further downside toward the next psychological level of $40. Resistance is at the 52-week high of $109.5, but more immediate resistance lies around $50-$55, where the stock traded in late May 2026. The beta of 0.577 indicates the stock is less volatile than the market, meaning the 57.9% decline is driven by company-specific factors rather than broad market moves. A breakout above $50 would signal a potential trend reversal, while a breakdown below $42.2 would confirm continued weakness.
Beta
0.58
0.58x market volatility
Max Drawdown
-60.6%
Largest decline past year
52-Week Range
$42-$110
Price range past year
Annual Return
-57.9%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | -2.0% | -0.5% |
| 3m | -31.4% | +4.9% |
| 6m | -50.0% | +9.7% |
| 1y | -57.9% | +18.4% |
| ytd | -53.5% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Boston Scientific's revenue trajectory remains solidly growing, with Q1 2026 revenue of $5.203 billion, up 11.6% year-over-year from $4.663 billion in Q1 2025. The multi-quarter trend shows accelerating growth: revenue grew from $4.12 billion in Q2 2024 to $5.203 billion in Q1 2026, with YoY growth rates improving from 7.8% in Q2 2024 to 11.6% in Q1 2026. The Cardiovascular segment, generating $3.493 billion in the latest quarter, is the primary growth driver, while MedSurg contributed $1.814 billion. This consistent double-digit growth supports the investment case for a company with strong product cycles and market expansion. Profitability is robust, with Q1 2026 net income of $1.337 billion and a net margin of 25.7%, up from 14.5% in Q1 2025. Gross margin improved to 69.4% from 63.3% a year earlier, reflecting operating leverage and product mix. Operating margin expanded to 20.6% from 19.2% in Q1 2025, indicating efficient cost management. The company is solidly profitable with a trailing PE of 48.6x, but the forward PE of 11.9x suggests significant earnings growth is expected. The balance sheet is healthy, with a debt-to-equity ratio of 0.51 and a current ratio of 1.62, indicating adequate liquidity. Free cash flow (TTM) is $3.442 billion, providing ample capacity for internal funding of growth initiatives and acquisitions. ROE stands at 11.9%, reflecting efficient capital use. The company does not pay a dividend, retaining earnings for reinvestment. Overall, the financial health is strong, with cash flow generation supporting the MiRus investment without straining the balance sheet.
Quarterly Revenue
$5.2B
2026-03
Revenue YoY Growth
+11.6%
YoY Comparison
Gross Margin
69.4%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Since net income is positive ($1.337 billion in Q1 2026), the primary valuation metric is the P/E ratio. The trailing P/E is 48.6x, while the forward P/E is 11.9x, implying the market expects a dramatic increase in earnings over the next year. This gap is unusually wide and suggests either the trailing earnings include one-time charges or the forward estimates are very optimistic; the forward P/E of 11.9x appears low relative to historical norms. Compared to the industry average (not provided), the stock's trailing P/E of 48.6x is likely at a premium to the medical devices sector, which typically trades around 20-30x. The forward P/E of 11.9x, however, would be a significant discount if realized, indicating the market is pricing in substantial earnings growth. The PEG ratio of 0.88 suggests the stock is undervalued relative to its growth rate, as a PEG below 1.0 is typically considered attractive. Historically, the stock's trailing P/E has ranged from roughly 17x (Q1 2026) to 189x (Q4 2021), with the current 48.6x near the middle of that range. However, the forward P/E of 11.9x is near the low end of historical forward multiples, suggesting the market is pricing in a recovery. The price-to-sales ratio of 7.0x is elevated compared to historical levels around 20x, but this is distorted by the sharp price decline. Overall, the valuation appears mixed: trailing multiples are high, but forward multiples and PEG suggest value if earnings materialize.
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~88x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the gap between trailing and forward P/E (48.6x vs. 11.9x), which implies the market expects a massive earnings jump. If Q1 2026's net income of $1.337 billion is not sustained or growth decelerates, the stock could re-rate lower. The $1.5 billion MiRus investment adds execution risk, as any delays or clinical setbacks could impair returns. Additionally, the company's debt-to-equity of 0.51 is manageable, but interest expense of $90 million per quarter could pressure margins if rates remain high.
Market & Competitive Risks: The stock's beta of 0.577 suggests lower market correlation, but the 57.9% decline indicates company-specific issues dominate. Competitive risks include Medtronic and Abbott in key markets like TAVR and cardiac rhythm management. The stock's trailing P/E of 48.6x is a premium to the sector, leaving it vulnerable to multiple compression if growth slows. Regulatory headwinds or adverse trial results (as seen on March 30) could further erode confidence. The 52-week low of $42.2 is a critical support; a break below could trigger stop-loss selling and a move toward $40.
Worst-Case Scenario: If the company fails to execute on the MiRus TAVR opportunity, faces a broader market downturn, or delivers disappointing earnings, the stock could fall to its 52-week low of $42.2 or below. A realistic worst-case target is $40, representing a 9.2% decline from the current price of $44.03. In a severe recession scenario, the stock could revisit the $35 level, implying a 20.5% loss. The maximum drawdown of 60.58% from the 52-week high of $109.5 illustrates the potential for significant downside.
FAQ
The key risks are: 1) Execution risk on the $1.5 billion MiRus TAVR investment — if clinical or commercial results disappoint, the stock could fall further. 2) Valuation risk — the trailing P/E of 48.6x leaves little room for error; any earnings miss could trigger multiple compression. 3) Technical risk — the stock is in a severe downtrend, down 57.9% in the past year, and a break below the 52-week low of $42.2 could lead to further declines. 4) Macro risk — a recession could reduce elective procedure volumes, impacting revenue growth. The most severe risk is a combination of these factors, which could push the stock to $35 or lower.
The 12-month forecast is based on three scenarios. The base case (50% probability) sees the stock recovering to the analyst average target of $72.5, driven by sustained revenue growth and margin expansion. The bull case (30% probability) targets $106, assuming successful TAVR market entry and multiple expansion. The bear case (20% probability) sees the stock testing the 52-week low of $42.2 or lower if growth disappoints. The most likely scenario is the base case, with the key assumption that the company delivers on its forward earnings estimates. The consensus analyst view is Strong Buy, supporting a positive outlook.
Boston Scientific's valuation is mixed. The trailing P/E of 48.6x is high relative to the medical devices sector average of 20-30x, suggesting the stock is expensive based on past earnings. However, the forward P/E of 11.9x is a deep discount, implying the market expects a dramatic increase in earnings. The PEG ratio of 0.88 (below 1.0) indicates the stock is undervalued relative to its growth rate. Historically, the stock's forward P/E has ranged from about 10x to 30x, so the current 11.9x is near the low end. Overall, the stock appears undervalued if the company delivers on its growth targets, but overvalued if earnings disappoint.
Boston Scientific presents a compelling risk/reward for investors with a medium-term horizon. The stock is down 57.9% over the past year, but the company's fundamentals remain strong: revenue grew 11.6% YoY, net margin expanded to 25.7%, and free cash flow is $3.4 billion. The average analyst target of $72.5 implies 64.7% upside, and the forward P/E of 11.9x is attractive. However, the stock is in a downtrend and trading near its 52-week low of $42.2, so near-term volatility is high. It is a good buy for those who can tolerate downside risk to $42 and have a 12-month horizon, but not for short-term traders or risk-averse investors.
Boston Scientific is better suited for long-term investment (12-24 months or more) rather than short-term trading. The stock has a beta of 0.577, indicating lower volatility than the market, but its recent 57.9% decline shows it can be highly volatile on a company-specific basis. The company does not pay a dividend, so total return depends on price appreciation. The strong fundamentals and attractive forward valuation support a long-term hold, but the negative momentum makes short-term timing risky. A minimum holding period of 12 months is recommended to allow the earnings story to play out and the stock to potentially recover toward analyst targets.
